Anika Therapeutics (ANIK) Tops Q1 EPS by 13c

Anika Therapeutics (NASDAQ: ANIK) reported Q1 EPS of ($0.11), $0.13 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $37.9 million versus the consensus estimate of $38.95 million.

For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• UBS Upgrades Apollo Tyres (APTY:IN) to Buy
• DA Davidson Reiterates Buy Rating on Box, Inc. (BOX) on Secular Tailwinds for Demand